Literature DB >> 9333170

Transmission of vaccine strain varicella-zoster virus from a healthy adult with vaccine-associated rash to susceptible household contacts.

P LaRussa1, S Steinberg, F Meurice, A Gershon.   

Abstract

Twelve days after receiving an investigational Oka strain live attenuated varicella vaccine, a 38-year-old healthy white woman developed a rash consisting of 30 scattered lesions. Sixteen days later, her 2 children also developed rash. Swabs obtained from the skin lesions of the vaccinee and her children demonstrated the presence of varicella-zoster virus (VZV) DNA by a polymerase chain reaction (PCR) assay. Restriction endonuclease polymorphisms present in wild and vaccine type VZV were examined, and the amplified VZV DNA was determined to be vaccine type. This case documents transmission of varicella vaccine type virus from a healthy vaccinee to susceptible household contacts. Since vaccine-associated rashes are uncommon and mild, it is likely that transmission of vaccine virus will also be uncommon. With widespread immunization beginning in the United States, ongoing studies will define the frequency of this transmission.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9333170     DOI: 10.1086/516514

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  16 in total

Review 1.  Varicella vaccination--a critical review of the evidence.

Authors:  S A Skull; E E Wang
Journal:  Arch Dis Child       Date:  2001-08       Impact factor: 3.791

2.  Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental virus.

Authors:  Yasuyuki Gomi; Hiroki Sunamachi; Yasuko Mori; Kazuhiro Nagaike; Michiaki Takahashi; Koichi Yamanishi
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

Review 3.  Vaccination in the primary care setting: when is it safe to proceed?

Authors:  Hui Lee Sharon Ngoh; Mark Chung Wai Ng
Journal:  Singapore Med J       Date:  2016-01       Impact factor: 1.858

4.  Novel genetic variation identified at fixed loci in ORF62 of the Oka varicella vaccine and in a case of vaccine-associated herpes zoster.

Authors:  Mark L Quinlivan; Nancy J Jensen; Kay W Radford; D Scott Schmid
Journal:  J Clin Microbiol       Date:  2012-02-29       Impact factor: 5.948

5.  Rapid genotyping of varicella-zoster virus vaccine and wild-type strains with fluorophore-labeled hybridization probes.

Authors:  V N Loparev; K McCaustland; B P Holloway; P R Krause; M Takayama; D S Schmid
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

6.  Varicella-zoster virus glycoproteins B and E are major targets of CD4+ and CD8+ T cells reconstituting during zoster after allogeneic transplantation.

Authors:  Patrick Kleemann; Eva Distler; Eva M Wagner; Simone Thomas; Sebastian Klobuch; Steffi Aue; Elke Schnürer; Hansjörg Schild; Matthias Theobald; Bodo Plachter; Stefan Tenzer; Ralf G Meyer; Wolfgang Herr
Journal:  Haematologica       Date:  2011-12-29       Impact factor: 9.941

Review 7.  Preventing varicella-zoster disease.

Authors:  Sophie Hambleton; Anne A Gershon
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

Review 8.  Transmission of Vaccine-Strain Varicella-Zoster Virus: A Systematic Review.

Authors:  Mona Marin; Jessica Leung; Anne A Gershon
Journal:  Pediatrics       Date:  2019-09       Impact factor: 7.124

9.  The varicella-zoster virus portal protein is essential for cleavage and packaging of viral DNA.

Authors:  Melissa A Visalli; Brittany L House; Anca Selariu; Hua Zhu; Robert J Visalli
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

10.  Detection and genotyping of varicella-zoster virus by TaqMan allelic discrimination real-time PCR.

Authors:  Paul A Campsall; Nicholas H C Au; Julie S Prendiville; David P Speert; Rusung Tan; Eva E Thomas
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.